[Dysfunction of the aldosterone synthesis pathway as a marker of malignity in symptomatic and asymptomatic adrenal masses].
Fundamental research performed in the author's laboratory led to the understanding of mechanisms of the mineralocorticoid biosynthetic pathway. Sensitive assays were then developed to allow measurement of the different mineralocorticoid metabolites in several biological fluids. Using these methods biological markers that contribute to the differential diagnosis between benign and malignant adrenal tumors were identified. In the present paper we report that the exploration of the entire mineralocorticoid pathway in the plasma of patients during basal state and after stimulation and/or inhibition test is a powerful tool to predict or validate diagnosis of adrenal malignancy. Moreover, mineralocorticoid exploration can help differentiate between two different types of malignancy, ie malignant cortical adrenaloma and metastases of other cancer. The biochemical mechanisms leading to the atypical mineralocorticoid metabolism in the case of malignant cortical adrenaloma are now under study.
Aupetit-Faisant
B
B
Service de Biochimie, CHU Pitié-Salpêtrière, Paris.
Blanchouin
N
N
Legrand
J C
JC
D000306:Adrenal Cortex Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D018246:Adrenocortical Adenoma / Q000175:diagnosis* / Q000378:metabolism; D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000096:biosynthesis*; D014408:Biomarkers, Tumor; D003345:Corticosterone / Q000096:biosynthesis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D006889:Hydroxycorticosteroids / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D008901:Mineralocorticoids / Q000096:biosynthesis; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000378:metabolism
D014408:Biomarkers, Tumor; D006889:Hydroxycorticosteroids; D008901:Mineralocorticoids; D000450:Aldosterone; D003345:Corticosterone
Du dysfonctionnement de la voie de synthèse de l'aldostérone comme marqueur de malignité des masses surrénaliennes symptomatiques et asymptomatiques.